US2020121689A1PendingUtilityA1

Use of non-peptide nk1 antagonists in a predetermined dose for the treatment of cancer

51
Assignee: SERVICIO ANDALUZ DE SALUDPriority: Dec 27, 2013Filed: Sep 23, 2019Published: Apr 23, 2020
Est. expiryDec 27, 2033(~7.4 yrs left)· nominal 20-yr term from priority
Inventors:Manuel Vicente Salinas Martin
A61K 31/5377A61K 45/06A61P 35/00A61K 33/24A61K 33/243
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Use of the non-peptide NK1 receptor antagonist, preferably Aprepitant, for the treatment of cancer in predetermined doses. The present invention also describes pharmaceutical compositions comprising said agents, alone or in combination with at least one other active principle, for the treatment of cancer

Claims

exact text as granted — not AI-modified
1 .- 14 . (canceled) 
     
     
         15 . A method of treating cancerous tumors in a mammal, said method comprising administering a composition comprising (a) aprepitant and (b) oxaliplatin or carboplatin, wherein the dose of aprepitant administered is between 5 and 120 mg/kg of weight per day, wherein the cancerous tumors are selected from the list consisting of lung cancer, glioma, fibrosarcoma, lymphoma, melanoma, and neuroblastoma. 
     
     
         16 . The method according to  claim 15 , wherein the dose of aprepitant administered is between 8 and 100 mg/kg of weight per day. 
     
     
         17 . The method according to  claim 16 , wherein the dose of aprepitant administered is between 10 and 80 mg/kg of weight per day. 
     
     
         18 . The method according to  claim 15 , wherein the dose of aprepitant administered is between 35 and 120 mg/kg of weight per day. 
     
     
         19 . The method according to  claim 15 , wherein the composition further comprises a pharmaceutically acceptable carrier. 
     
     
         20 . The method according to  claim 15 , wherein the cancerous tumors present with alteration of the peritumoral environment. 
     
     
         21 . The method according to  claim 15 , wherein the cancerous tumors that present with peritumoral alteration show an increased synthesis of the markers selected from the group consisting of: NF-kB, EGF, VEGF, TNF-α, TGF-α, TGF-β 1, TGF-β 2, TGF-β 3, SPARC, MMP-3; MMP-7, MMP-9, MMP-11, MMP-13, MMP-14, and combinations thereof. 
     
     
         22 . The method according to  claim 15 , wherein the mammal is a human.

Join the waitlist — get patent alerts

Track US2020121689A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.